05/05/2026

Recent Oncology Related FDA Approvals and Expanded Indications

FDA approves BeOne's sonrotoclax (Beqalzi), a BCL-2 inhibitor, for adults with relapsed or refractory mantel cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor

FDA approves Taiho's INQOVI plus Venetoclax for adults with newly diagnosed acute myeloid leukemia (AML) aged 75 or older or ineligible for intensive induction chemotherapy

More Info